Facilitated By

San Antonio Medical Foundation

Trending Research

Top viewed research performed by San Antonio Bioscience Organizations


The primary objective of the study is to compare the overall response rate (inclusive of complete response, partial response and hematologic improvement) per IWG 2006 criteria in patients with higher risk MDS treated with azacitidine with or without deferasirox achieved over the course of one year. Hematologic improvement must be maintained for at least 8 weeks.

Brooke Army Medical Center
Email for information

This study includes patients that have been treated for node-positive (NP) or high-risk node-negative (NN) breast cancer where they are at risk for recurrence (breast cancer coming back); and also because tumor cells show a specific protein called HER2/neu on their cell surfaces. “Node-positive” means that breast cancer has been found in the lymph nodes.

Cancer Insight, LLC
George Peoples